Tag: gastric cancer drugs market demand

Claim 20% Off Global Market Reports With Code ONLINE20 – Insights on Tariff Effects, Global Trade, and Industry Disruptors

What Is The Predicted Market Size Of The Gastric Cancer Drugs Industry By 2029?

The market size for gastric cancer drugs has witnessed a robust expansion in recent years. The growth is predicted to escalate from $4.41 billion in 2024 to $4.9 billion in 2025, registering a compound annual growth rate (CAGR) of 11.2%. Factors contributing to this growth in the past can be traced back to increased investment in pharmaceutical research and development, rise in healthcare spending, significant economic progress in budding markets, and a swift increase in the older demographic.

In the coming years, the market for gastric cancer medications is predicted to experience quick expansion, anticipating a culmination of $7.35 billion in 2029, with a Compound Annual Growth Rate (CAGR) of 10.7%. Numerous factors have led to this estimated growth, including an increase in gastric cancer incidents, a robust pipeline of potential drugs, heightened levels of healthcare spending, growing mergers and collaborations, a larger aged population, and updates to FDA rules to smooth the progress of biologic drug production. The forecast period is marked by key movements such as strategic partnerships to expand product ranges, joint ventures with other firms or governmental entities, raising the quantity of pipeline research to generate new gastric cancer drugs, the incorporation of AI technologies to lower R&D expenses, the creation of new-generation biologics and the application of CRISPR-cas9 technology in the development of new pharmaceuticals.

Get A Free Sample Of The Report:

https://www.thebusinessresearchcompany.com/sample.aspx?id=2603&type=smp

What External And Internal Drivers Are Influencing The Gastric Cancer Drugs Market?

The rising instances of obesity and smoking have contributed to an upsurge in the number of gastric cancer patients. The habit of tobacco consumption and adherence to an unhealthy diet are key risk factors for stomach cancer. As reported by the Government Digital Service of the UK in May 2023, it was predicted that 25.9% of individuals in England (those aged 18 years and above) were obese in 2022–2022, an increase from 25.2%. This escalation in the number of gastric cancer cases instigates the growth of the market for gastric cancer drugs.

What Are The Primary Segmentation Parameters In The Gastric Cancer Drugs Market?

The gastric cancer drugs market covered in this report is segmented –

1) By Type: Imatinib, Trastuzumab, Other Types

2) By Route of Administration: Oral, Parenteral

3) By End User: Hospitals, Clinics, Cancer Speciality Centers

Subsegments:

1) By Imatinib: Oral Formulations, Injectable Formulations, Combination Therapies

2) By Trastuzumab: Monotherapy, Combination Therapy With Chemotherapy, Biosimilars Of Trastuzumab

3) By Other Types: Chemotherapy Agents, Targeted Therapy Agents, Immunotherapy Agents, Supportive Care Medications

Which Emerging Trends Are Reshaping The Gastric Cancer Drugs Market Landscape?

Numerous organizations in the gastric cancer drugs market are devising advanced solutions, including anti-PD-1 therapies, to boost therapeutic effectiveness and refine patient outcomes. Anti-PD-1 therapy is an immunotherapy form that aims at the programmed cell death protein 1 (PD-1) receptor located on immune cells. One such example is in November 2023 when Merck & Co., Inc., a pharmaceutical firm based in the US, attained approval from the US federal agency dedicated to public health protection, the Food and Drug Administration (FDA), for KEYTRUDA (pembrolizumab). Approximated for use in treating gastric cancer, KEYTRUDA (pembrolizumab) is recommended as a front-line treatment for patients suffering from locally advanced, non-resectable, or metastatic HER2-positive gastric or gastroesophageal junction (GEJ) adenocarcinoma. This particular recommendation is for usage in conjunction with trastuzumab, plus fluoropyrimidine and platinum-based chemotherapy. The approval for this indication has been expedited given its impact on tumor response rate and the response duration.

Who Are The Dominant Players In The Gastric Cancer Drugs Market Today?

Major companies operating in the gastric cancer drugs market include F. Hoffmann-La Roche, Eli Lilly and Company, Otsuka Pharmaceutical, Jiangsu HengRui Medicine, Biocon, Sanofi, PV Pharma Healthcare (India), Roche India, Novartis Oncology, Arlak Biotech (India), Healthkind labs Pvt. Ltd., SwisscheM Healthcare Pvt.Ltd, Apikos Pharma, Kolaz biotech., CStone Pharma (China), CARsgen Therapeutics (China), JW Therapeutics (China), BeiGene(China), Takeda Pharmaceuticals (Japan), Astellas Pharma Inc (Japan), Daiichi Pharmaceutical and Sankyo (Japan), AQVIDA GmbH, AstraZeneca plc, GlaxoSmithKline plc, Veropharm, Biocad, Bristol-Myers Squibb, Celon Pharma, Celltrion Inc., Imugene Limited, Merck & Co. Inc., Pfizer Inc., Sandoz AG (A Novartis Division), Eurofarma Laboratórios S.A., TUTEUR ArgentinaPierre Fabre Group, Celnova Pharma, Johnson & Johnson, Teva Pharmaceutical Industries Ltd., Saudi Pharmaceutical Industries and Medical Appliances Corporation (SPIMACO), Gulf Pharmaceutical Industries (Julphar), Abbott Laboratories, Mylan Laboratories, Gilead Sciences, BMS, Ascedis Health

Access The Complete Report Here:

https://www.thebusinessresearchcompany.com/report/gastric-cancer-drugs-global-market-report

What Are The Emerging Regional Trends Driving The Gastric Cancer Drugs Market?

North America was the largest region in the gastric cancer drugs market in 2024. Middle East is expected to be the largest growing region in the global gastric cancer drugs market share during the forecast period. The regions covered in the gastric cancer drugs market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa

Customize Your Report Here:

https://www.thebusinessresearchcompany.com/customise?id=2603&type=smp

About The Business Research Company:

With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795

Asia +44 7882 955267 & +91 8897263534

Europe +44 7882 955267

Email us at info@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

Claim your 30% discount on Global Market Reports with code ONLINE30. Limited time only.

Claim your 30% discount on Global Market Reports with code ONLINE30. Limited time only.

How Much Is the Global Gastric Cancer Drugs Market Valued at Present and by 2029?

The market size for drugs dealing with gastric cancer has surged in recent times. The value of the market is expected to advance from $4.41 billion in 2024 to $4.9 billion in 2025, showing a compound annual growth rate (CAGR) of 11.2%. The past growth was due to factors such as rise in R&D spending in the pharmaceutical industry, increased health care costs, robust economic growth in developing regions, and a fast-growing elderly population.

The market for drugs treating gastric cancer is predicted to experience substantial growth in the coming years. It is projected to expand to “$7.35 billion by 2029 with a compound annual growth rate (CAGR) of 10.7%. This growth throughout the forecast period can be associated with an increasing incidence of gastric cancer, a robust drug pipeline, an uptick in mergers and collaborations, increased healthcare spending, an aging population, and amended FDA regulations that encourages the progression of biologics drugs. Main trends emerging in the forecast period include strategic partnerships and contracts aimed at expanding product range, collaborations with other organizations or government agencies, increasing pipeline studies for the development of gastric cancer drugs, investing in AI technologies to lower R&D expenses, creation of next-gen biologics, and the application of CRISPR-cas9 technology in the development of novel drugs.

Download The Free Sample Report Here:

https://www.thebusinessresearchcompany.com/sample.aspx?id=2603&type=smp

#What Drivers Are Influencing Growth In The Gastric Cancer Drugs Market?

The rise in obesity and the growing number of smokers have led to an increase in people being afflicted with gastric cancer. Unhealthy dietary habits and tobacco consumption escalate the danger of developing stomach cancer. As cited by the UK’s Government Digital Service, it was estimated in May 2023 that the obesity rate amongst individuals aged 18 and above in England had grown from 25.2% in 2022 to 25.9%. As the number of gastric cancer cases rises, so does the demand for gastric cancer medications, thus promoting market growth.

The gastric cancer drugs market covered in this report is segmented –

1) By Type: Imatinib, Trastuzumab, Other Types

2) By Route of Administration: Oral, Parenteral

3) By End User: Hospitals, Clinics, Cancer Speciality Centers

Subsegments:

1) By Imatinib: Oral Formulations, Injectable Formulations, Combination Therapies

2) By Trastuzumab: Monotherapy, Combination Therapy With Chemotherapy, Biosimilars Of Trastuzumab

3) By Other Types: Chemotherapy Agents, Targeted Therapy Agents, Immunotherapy Agents, Supportive Care Medications

What Are The Leading Trends And Opportunities In The Gastric Cancer Drugs Sector?

In the gastric cancer drugs market, numerous firms are developing innovative products, such as anti-PD-1 therapies, to improve treatment results and patient prognosis. Anti-PD-1 therapy is an immunotherapy that targets the PD-1 receptor found on immune cells. For example, in November 2023, US-based pharmaceutical company Merck & Co., Inc. was granted approval by the Food and Drug Administration (FDA) for KEYTRUDA (pembrolizumab), an anti-PD-1 therapy for gastric cancer treatment. KEYTRUDA (pembrolizumab), specifically for combination use with trastuzumab and fluoropyrimidine- and platinum-based chemotherapy, is a first-line treatment for patients with locally advanced inoperable or metastatic HER2-positive gastric or gastroesophageal junction (GEJ) adenocarcinoma. The rapid approval was given based on the rate of tumor response and the length of that response.

Which Companies Play A Key Role In The Development Of The Gastric Cancer Drugs Market?

Major companies operating in the gastric cancer drugs market include F. Hoffmann-La Roche, Eli Lilly and Company, Otsuka Pharmaceutical, Jiangsu HengRui Medicine, Biocon, Sanofi, PV Pharma Healthcare (India), Roche India, Novartis Oncology, Arlak Biotech (India), Healthkind labs Pvt. Ltd., SwisscheM Healthcare Pvt.Ltd, Apikos Pharma, Kolaz biotech., CStone Pharma (China), CARsgen Therapeutics (China), JW Therapeutics (China), BeiGene(China), Takeda Pharmaceuticals (Japan), Astellas Pharma Inc (Japan), Daiichi Pharmaceutical and Sankyo (Japan), AQVIDA GmbH, AstraZeneca plc, GlaxoSmithKline plc, Veropharm, Biocad, Bristol-Myers Squibb, Celon Pharma, Celltrion Inc., Imugene Limited, Merck & Co. Inc., Pfizer Inc., Sandoz AG (A Novartis Division), Eurofarma Laboratórios S.A., TUTEUR ArgentinaPierre Fabre Group, Celnova Pharma, Johnson & Johnson, Teva Pharmaceutical Industries Ltd., Saudi Pharmaceutical Industries and Medical Appliances Corporation (SPIMACO), Gulf Pharmaceutical Industries (Julphar), Abbott Laboratories, Mylan Laboratories, Gilead Sciences, BMS, Ascedis Health

https://www.thebusinessresearchcompany.com/report/gastric-cancer-drugs-global-market-report

What Are The Key Regional Developments Shaping The Gastric Cancer Drugs Market?

North America was the largest region in the gastric cancer drugs market in 2024. Middle East is expected to be the largest growing region in the global gastric cancer drugs market share during the forecast period. The regions covered in the gastric cancer drugs market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa

Request For A Customized Report:

https://www.thebusinessresearchcompany.com/customise?id=2603&type=smp

About The Business Research Company:

With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795

Asia +44 7882 955267 & +91 8897263534

Europe +44 7882 955267

Email us at info@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

Claim your 30% discount on Global Market Reports with code ONLINE30. Limited time only.

What Are the Key Projections for the CAGR of the Gastric Cancer Drugs Market Size From 2025 to 2034?

There has been a swift expansion of the market size for gastric cancer drugs in the past few years. This market is projected to increase from $4.41 billion in 2024 to around $4.9 billion in 2025, reflecting a compound annual growth rate (CAGR) of 11.2%. Factors such as rising pharmaceutical R&D spending, escalated healthcare expenses, robust economic growth in developing markets and a skyrocketing elderly population have contributed to the historical growth of this market.

In the next few years, the market for gastric cancer drugs is projected to experience rapid expansion. The anticipation is for a growth to $7.35 billion by 2029, with a Compound Annual Growth Rate (CAGR) of 10.7%. This growth in the forecasted period can be credited to a rise in the incidence rate of gastric cancer, a solid pipeline of medications, increased healthcare expenditure, and updated FDA guidelines to assist the development of biologics drugs. The period also sees an uptick in acquisitions and partnerships, an aging population, and the progression of strong drug pipelines. Major trends within this period involve strategic collaborations and agreements to expand product ranges, partnerships with other businesses or governmental entities, an increased number of pipeline studies conducted for the development of gastric cancer drugs, investments in AI to lower R&D expenses, the progression of next-gen biologics, and the application of CRISPR-cas9 technology in creating new drugs.

Download a free sample to assess the report’s scope and structure:

https://www.thebusinessresearchcompany.com/sample.aspx?id=2603&type=smp

What Are the Core Growth Drivers Propelling the Gastric Cancer Drugs Market Forward?

The rise in obesity rates and the number of smokers has resulted in a heightened number of gastric cancer cases. Unhealthy dietary practices and tobacco consumption heighten the risk of developing stomach cancer. For example, predictions from the Government Digital Service, a UK-based government body, in May 2023 indicated that in England, 25.9% of people (aged 18 and over) were obese in 2022–2022, marking an increase from the previous 25.2%. This surge in gastric cancer incidents is expected to propel the growth of the gastric cancer drugs market.

What Segment Types Define the Gastric Cancer Drugs Market Structure?

The gastric cancer drugs market covered in this report is segmented –

1) By Type: Imatinib, Trastuzumab, Other Types

2) By Route of Administration: Oral, Parenteral

3) By End User: Hospitals, Clinics, Cancer Speciality Centers

Subsegments:

1) By Imatinib: Oral Formulations, Injectable Formulations, Combination Therapies

2) By Trastuzumab: Monotherapy, Combination Therapy With Chemotherapy, Biosimilars Of Trastuzumab

3) By Other Types: Chemotherapy Agents, Targeted Therapy Agents, Immunotherapy Agents, Supportive Care Medications

Request customized data on this market:

https://www.thebusinessresearchcompany.com/customise?id=2603&type=smp

Which Geographic Areas Hold the Strongest Growth Potential in the Gastric Cancer Drugs Market?

North America was the largest region in the gastric cancer drugs market in 2024. Middle East is expected to be the largest growing region in the global gastric cancer drugs market share during the forecast period. The regions covered in the gastric cancer drugs market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa

Which Emerging Trends that Are Influencing theGastric Cancer Drugs Industry Evolution?

Numerous businesses in the gastric cancer drugs industry are pioneering novel products like anti-PD-1 therapies in order to amplify the effectiveness of treatments and betterment of patients. Anti-PD-1 treatment is an immunotherapy that targets the programmed cell death protein 1 (PD-1) receptor on immune cells. For example, in November 2023, Merck & Co., Inc., a pharmaceutical firm based in the US, was given the green light by the Food and Drug Administration (FDA), a federal agency in the US responsible for ensuring public health, for KEYTRUDA (pembrolizumab). KEYTRUDA (pembrolizumab) is an anti-PD-1 therapy employed to treat gastric cancer. Specifically, it’s meant for initial treatment of patients suffering from locally advanced irreparable or metastatic HER2-positive gastric or gastroesophageal junction (GEJ) adenocarcinoma. This treatment is intended for use in combination with trastuzumab, as well as fluoropyrimidine- and platinum-containing chemotherapy, and has been granted accelerated approval based on tumor response rate and the duration of said response.

View the full report here:

https://www.thebusinessresearchcompany.com/report/gastric-cancer-drugs-global-market-report

What Is the Definition of the Gastric Cancer Drugs Market?

Gastric cancer drugs refer to anti-cancer medications that are taken orally as pills or are injected into a vein (via an IV line or central venous catheter). This treatment is effective for cancer that has spread to organs other than those where it originated since these medications penetrate the bloodstream and reach every part of the body.

Purchase the full report and get a swift delivery:

https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=2603

About The Business Research Company:

With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795

Europe +44 7882 955267

Asia & Others +44 7882 955267 & +91 8897263534

Email us at info@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

Claim your 30% discount on Global Market Reports with code ONLINE30. Limited time only.

#What Are the Key Projections for the CAGR of the Gastric Cancer Drugs Market Size From 2025 to 2034?#_x000D_

There has been a swift expansion of the market size for gastric cancer drugs in the past few years. This market is projected to increase from $4.41 billion in 2024 to around $4.9 billion in 2025, reflecting a compound annual growth rate (CAGR) of 11.2%. Factors such as rising pharmaceutical R&D spending, escalated healthcare expenses, robust economic growth in developing markets and a skyrocketing elderly population have contributed to the historical growth of this market._x000D_

_x000D_

In the next few years, the market for gastric cancer drugs is projected to experience rapid expansion. The anticipation is for a growth to $7.35 billion by 2029, with a Compound Annual Growth Rate (CAGR) of 10.7%. This growth in the forecasted period can be credited to a rise in the incidence rate of gastric cancer, a solid pipeline of medications, increased healthcare expenditure, and updated FDA guidelines to assist the development of biologics drugs. The period also sees an uptick in acquisitions and partnerships, an aging population, and the progression of strong drug pipelines. Major trends within this period involve strategic collaborations and agreements to expand product ranges, partnerships with other businesses or governmental entities, an increased number of pipeline studies conducted for the development of gastric cancer drugs, investments in AI to lower R&D expenses, the progression of next-gen biologics, and the application of CRISPR-cas9 technology in creating new drugs._x000D_

_x000D_

#Download a free sample to assess the report’s scope and structure:#_x000D_

https://www.thebusinessresearchcompany.com/sample.aspx?id=2603&type=smp_x000D_

_x000D_

#What Are the Core Growth Drivers Propelling the Gastric Cancer Drugs Market Forward?#_x000D_

The rise in obesity rates and the number of smokers has resulted in a heightened number of gastric cancer cases. Unhealthy dietary practices and tobacco consumption heighten the risk of developing stomach cancer. For example, predictions from the Government Digital Service, a UK-based government body, in May 2023 indicated that in England, 25.9% of people (aged 18 and over) were obese in 2022–2022, marking an increase from the previous 25.2%. This surge in gastric cancer incidents is expected to propel the growth of the gastric cancer drugs market._x000D_

_x000D_

#What Segment Types Define the Gastric Cancer Drugs Market Structure?#_x000D_

The gastric cancer drugs market covered in this report is segmented – _x000D_

_x000D_

1) By Type: Imatinib, Trastuzumab, Other Types_x000D_

2) By Route of Administration: Oral, Parenteral_x000D_

3) By End User: Hospitals, Clinics, Cancer Speciality Centers_x000D_

_x000D_

Subsegments:_x000D_

1) By Imatinib: Oral Formulations, Injectable Formulations, Combination Therapies_x000D_

2) By Trastuzumab: Monotherapy, Combination Therapy With Chemotherapy, Biosimilars Of Trastuzumab_x000D_

3) By Other Types: Chemotherapy Agents, Targeted Therapy Agents, Immunotherapy Agents, Supportive Care Medications _x000D_

_x000D_

#Request customized data on this market:#_x000D_

https://www.thebusinessresearchcompany.com/customise?id=2603&type=smp_x000D_

_x000D_

#Which Geographic Areas Hold the Strongest Growth Potential in the Gastric Cancer Drugs Market?#_x000D_

North America was the largest region in the gastric cancer drugs market in 2024. Middle East is expected to be the largest growing region in the global gastric cancer drugs market share during the forecast period. The regions covered in the gastric cancer drugs market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa_x000D_

_x000D_

#Which Emerging Trends that Are Influencing theGastric Cancer Drugs Industry Evolution?#_x000D_

Numerous businesses in the gastric cancer drugs industry are pioneering novel products like anti-PD-1 therapies in order to amplify the effectiveness of treatments and betterment of patients. Anti-PD-1 treatment is an immunotherapy that targets the programmed cell death protein 1 (PD-1) receptor on immune cells. For example, in November 2023, Merck & Co., Inc., a pharmaceutical firm based in the US, was given the green light by the Food and Drug Administration (FDA), a federal agency in the US responsible for ensuring public health, for KEYTRUDA (pembrolizumab). KEYTRUDA (pembrolizumab) is an anti-PD-1 therapy employed to treat gastric cancer. Specifically, it’s meant for initial treatment of patients suffering from locally advanced irreparable or metastatic HER2-positive gastric or gastroesophageal junction (GEJ) adenocarcinoma. This treatment is intended for use in combination with trastuzumab, as well as fluoropyrimidine- and platinum-containing chemotherapy, and has been granted accelerated approval based on tumor response rate and the duration of said response._x000D_

_x000D_

#View the full report here:#_x000D_

https://www.thebusinessresearchcompany.com/report/gastric-cancer-drugs-global-market-report_x000D_

_x000D_

#What Is the Definition of the Gastric Cancer Drugs Market?#_x000D_

Gastric cancer drugs refer to anti-cancer medications that are taken orally as pills or are injected into a vein (via an IV line or central venous catheter). This treatment is effective for cancer that has spread to organs other than those where it originated since these medications penetrate the bloodstream and reach every part of the body._x000D_

_x000D_

#Purchase the full report and get a swift delivery:#_x000D_

https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=2603_x000D_

_x000D_

#About The Business Research Company:#_x000D_

With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game._x000D_

_x000D_

#Get in touch with us:#_x000D_

The Business Research Company: https://www.thebusinessresearchcompany.com/_x000D_

Americas +1 310-496-7795_x000D_

Europe +44 7882 955267_x000D_

Asia & Others +44 7882 955267 & +91 8897263534_x000D_

Email us at info@tbrc.info_x000D_

_x000D_

#Follow us on:#_x000D_

_x000D_

LinkedIn: https://in.linkedin.com/company/the-business-research-company_x000D_

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ_x000D_

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

2025 Market Reports Update: Market Size Forecasts to 2034, Key Trends, Leading Players, and Top Regions – Get Ahead of the Competition Today!

What External and Internal Drivers Are Contributing to the Growth of theGastric Cancer Drugs Market?

The rise in instances of obesity and the smoking population have resulted in an escalation in gastric cancer patients. Consumption of tobacco and unhealthy dietary habits amplify the risk of developing stomach cancer. To illustrate, in May 2023, the Government Digital Service of the United Kingdom reported that in England, the obesity rate among individuals aged 18 and over in 2022-2022 was approximately 25.9%, witnessing an upsurge from 25.2%. Consequently, the expected growth in gastric cancer cases will drive the progression of the gastric cancer drugs market.

Get Your Free Sample Report Now – Explore Exclusive Market Insights:

https://www.thebusinessresearchcompany.com/sample.aspx?id=2603&type=smp

#What Long-Term Growth Rate is Expected for theGastric Cancer Drugs Market Between 2025 and 2034?

The market size for gastric cancer drugs has significantly expanded in the past few years. It is projected to rise from $4.43 billion in 2024 to $5.01 billion in 2025, demonstrating a compound annual growth rate (CAGR) of 12.9%. Factors such as the surge in pharmaceutical research and development spending, higher healthcare expenses, robust economic progression in developing markets, and a quickly ageing population have contributed to this growth during the historic period.

The market size of drugs for gastric cancer is anticipated to experience a rapid surge in the coming years: projections show it reaching $7.6 billion by 2029 with an 11.0% compound annual growth rate (CAGR). The forecasted growth can be credited to several factors, including a rise in the occurrence of gastric cancer, a robust drug pipeline, growing healthcare expenditure, an aging population, progressive acquisitions and collaborations, as well as updates to FDA regulations encouraging the development of biologics drugs. Significant trends for the period will be strategic alliances and partnerships for expanding product ranges, joint ventures with other firms or government agencies, increased focus on pipeline studies for the creation of drugs for gastric cancer, the adoption of AI to decrease R&D expenses, the production of next-gen biologics, and the utilization of CRISPR-cas9 technology in the development of new drugs.

You can Directly Purchase the Report Here:

https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=2603

Which Upcoming Market Trends and Innovations Are Set to Influence theGastric Cancer Drugs Market’s Path Forward?

A plethora of corporations involved in the gastric cancer drugs market are bringing forth advanced offerings, such as anti-PD-1 therapies, to boost treatment effectiveness and better patient prognosis. Anti-PD-1 therapy, an immunotherapy variant, targets the programmed cell death protein 1 (PD-1) receptor situated on immune cells. For illustration, in November 2023, a US-based pharmaceutical firm, Merck & Co., Inc., obtained approval from the Food and Drug Administration (FDA), a US federal agency dedicated to safeguarding public health for KEYTRUDA (pembrolizumab). This anti-PD-1 therapy, KEYTRUDA (pembrolizumab), is utilized in the treatment of gastric cancer. Moreover, it is recommended as the initial treatment for patients affected by locally advanced unresectable or metastatic HER2-positive gastric or gastroesophageal junction (GEJ) adenocarcinoma. It should be used in conjunction with trastuzumab and fluoropyrimidine- and platinum-based chemotherapy specifically. This indication has been awarded rapid approval based on the tumor response rate and the sustained period of such response.

Who Are the Dominant Market Players Pushing the Boundaries of theGastric Cancer Drugs Market?

Major companies operating in the gastric cancer drugs market include F. Hoffmann-La Roche, Eli Lilly and Company, Otsuka Pharmaceutical, Jiangsu HengRui Medicine, Biocon, Sanofi, PV Pharma Healthcare (India), Roche India, Novartis Oncology, Arlak Biotech (India), Healthkind labs Pvt. Ltd., SwisscheM Healthcare Pvt.Ltd, Apikos Pharma, Kolaz biotech., CStone Pharma (China), CARsgen Therapeutics (China), JW Therapeutics (China), BeiGene(China), Takeda Pharmaceuticals (Japan), Astellas Pharma Inc (Japan), Daiichi Pharmaceutical and Sankyo (Japan), AQVIDA GmbH, AstraZeneca plc, GlaxoSmithKline plc, Veropharm, Biocad, Bristol-Myers Squibb, Celon Pharma, Celltrion Inc., Imugene Limited, Merck & Co. Inc., Pfizer Inc., Sandoz AG (A Novartis Division), Eurofarma Laboratórios S.A., TUTEUR ArgentinaPierre Fabre Group, Celnova Pharma, Johnson & Johnson, Teva Pharmaceutical Industries Ltd., Saudi Pharmaceutical Industries and Medical Appliances Corporation (SPIMACO), Gulf Pharmaceutical Industries (Julphar), Abbott Laboratories, Mylan Laboratories, Gilead Sciences, BMS, Ascedis Health

Order Your Report Now For A Swift Delivery:

https://www.thebusinessresearchcompany.com/report/gastric-cancer-drugs-global-market-report

What Are the Core Segments of the Gastric Cancer Drugs Market, and How Do They Contribute to Growth?

The gastric cancer drugs market covered in this report is segmented –

1) By Type: Imatinib, Trastuzumab, Other Types

2) By Route of Administration: Oral, Parenteral

3) By End User: Hospitals, Clinics, Cancer Speciality Centers

Subsegments:

1) By Imatinib: Oral Formulations, Injectable Formulations, Combination Therapies

2) By Trastuzumab: Monotherapy, Combination Therapy With Chemotherapy, Biosimilars Of Trastuzumab

3) By Other Types: Chemotherapy Agents, Targeted Therapy Agents, Immunotherapy Agents, Supportive Care Medications

Gain Exclusive Market Insights—Customize Your Research Report Today for Fast Delivery!

https://www.thebusinessresearchcompany.com/customise?id=2603&type=smp

What Regions Are Dominating the Gastric Cancer Drugs Market Growth?

North America was the largest region in the gastric cancer drugs market in 2024. Middle East is expected to be the largest growing region in the global gastric cancer drugs market share during the forecast period. The regions covered in the gastric cancer drugs market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa

Browse Through More Reports Similar to the Global Gastric Cancer Drugs Market 2025, By The Business Research Company:

Oil And Gas Upstream Activities Global Market Report 2024

https://www.thebusinessresearchcompany.com/report/oil-and-gas-upstream-activities-global-market-report

Industrial And Commercial Natural Gas Distribution Global Market Report 2024

https://www.thebusinessresearchcompany.com/report/industrial-and-commercial-natural-gas-distribution-global-market-report

Oil And Gas Global Market Report 2024

https://www.thebusinessresearchcompany.com/report/oil-and-gas-global-market-report

About The Business Research Company:

With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.

Contact us at:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 3156230293

Asia +44 2071930708

Europe +44 2071930708

Email us at info@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

Found this article helpful? Share it on:

Updated 2025 Market Reports Released: Trends, Forecasts to 2034 – Early Purchase Your Competitive Edge Today!

What key factors are powering the surge in the gastric cancer drugs market right now?

The market size for drugs used to treat gastric cancer has been expanding quickly in the past few years. Predictions show its growth from $4.43 billion in 2024 to $5.01 billion in 2025, marking a compound annual growth rate (CAGR) of 12.9%. This historic growth is associated with the heightened spending on pharmaceutical research and development, boost in healthcare expenses, positive economic growth in developing markets, and the swift expansion of the senior population.

How fast Is the gastric cancer drugs market expected to grow, and what’s its future value?

The market for generative AI is anticipated to experience tremendous expansion in the upcoming years, reaching $113.42 billion by 2029, with a compound annual growth rate (CAGR) of 34.7%. The surge during this projected period can be accredited to progress in AI hardware technologies, integration across various industries, considerations around ethical AI, independent systems, and the implementation of edge computing. Key trends in this period are expected to be the increase in AI-created content, customization and personalization, applications across different domains, addressing bias in AI ethically, and cooperation between humans and AI.

Get your gastric cancer drugs market report here!

https://www.thebusinessresearchcompany.com/report/gastric-cancer-drugs-global-market-report

What are the leading drivers of growth in the gastric cancer drugs market?

The rise in the number of people with obesity and the growing smoking population has led to a surge in individuals battling gastric cancer. Unhealthy dietary habits and tobacco use escalate the risk of developing this type of cancer. For example, the Government Digital Service, a governmental entity in the UK, reported in May 2023 that the obesity rate among individuals 18 and older in England, had jumped to 25.9% in 2022–2022 from 25.2%. This escalating trend in the incidence of gastric cancer is likely to stimulate the growth of the gastric cancer drugs market.

What are the key segments defining the gastric cancer drugs market?

The gastric cancer drugs market covered in this report is segmented –

1) By Type: Imatinib, Trastuzumab, Other Types

2) By Route of Administration: Oral, Parenteral

3) By End User: Hospitals, Clinics, Cancer Speciality Centers

Subsegments:

1) By Imatinib: Oral Formulations, Injectable Formulations, Combination Therapies

2) By Trastuzumab: Monotherapy, Combination Therapy With Chemotherapy, Biosimilars Of Trastuzumab

3) By Other Types: Chemotherapy Agents, Targeted Therapy Agents, Immunotherapy Agents, Supportive Care Medications

Get your free sample now – explore exclusive market insights:

https://www.thebusinessresearchcompany.com/sample.aspx?id=2603&type=smp

Who are the key players steering the development of the gastric cancer drugs market?

Major companies operating in the gastric cancer drugs market include F. Hoffmann-La Roche, Eli Lilly and Company, Otsuka Pharmaceutical, Jiangsu HengRui Medicine, Biocon, Sanofi, PV Pharma Healthcare (India), Roche India, Novartis Oncology, Arlak Biotech (India), Healthkind labs Pvt. Ltd., SwisscheM Healthcare Pvt.Ltd, Apikos Pharma, Kolaz biotech., CStone Pharma (China), CARsgen Therapeutics (China), JW Therapeutics (China), BeiGene(China), Takeda Pharmaceuticals (Japan), Astellas Pharma Inc (Japan), Daiichi Pharmaceutical and Sankyo (Japan), AQVIDA GmbH, AstraZeneca plc, GlaxoSmithKline plc, Veropharm, Biocad, Bristol-Myers Squibb, Celon Pharma, Celltrion Inc., Imugene Limited, Merck & Co. Inc., Pfizer Inc., Sandoz AG (A Novartis Division), Eurofarma Laboratórios S.A., TUTEUR ArgentinaPierre Fabre Group, Celnova Pharma, Johnson & Johnson, Teva Pharmaceutical Industries Ltd., Saudi Pharmaceutical Industries and Medical Appliances Corporation (SPIMACO), Gulf Pharmaceutical Industries (Julphar), Abbott Laboratories, Mylan Laboratories, Gilead Sciences, BMS, Ascedis Health

What emerging trends are influencing the growth of the gastric cancer drugs market?

Leading firms in the gastric cancer drugs market, like Merck & Co., Inc., are developing innovative offerings such as anti-PD-1 therapies to bolster treatment efficiency and enhance patient recovery. Anti-PD-1 therapy, a form of immunotherapy, targets the programmed cell death protein 1 (PD-1) receptor found on immune cells. As an example, in November 2023, the US-based pharmaceutical company Merck & Co., Inc. obtained approval from the Food and Drug Administration (FDA), responsible for public health protection in the US, for the use of KEYTRUDA (pembrolizumab), an anti-PD-1 therapy used in gastric cancer treatment. KEYTRUDA is designed for first-line treatment of patients suffering from locally advanced cancer that is unresectable or metastatic HER2-positive gastric or gastroesophageal junction (GEJ) adenocarcinoma. It is specifically imported for use with trastuzumab and chemotherapy that contains fluoropyrimidine and platinum. The approval for this indication was fast-tracked based on the tumor response rate along with response duration.

Unlock exclusive market insights – purchase your research report now for a swift delivery!

https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=2603

Which regions are most influential in expanding the gastric cancer drugs market?

North America was the largest region in the gastric cancer drugs market in 2024. Middle East is expected to be the largest growing region in the global gastric cancer drugs market share during the forecast period. The regions covered in the gastric cancer drugs market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa

Browse Through More Similar Reports By The Business Research Company:

Diuretics Global Market Report 2024

https://www.thebusinessresearchcompany.com/report/diuretics-drugs-global-market-report

Genito-Urinary Drugs Global Market Report 2022

https://www.thebusinessresearchcompany.com/report/genito-urinary-drugs-global-market-report

Musculoskeletal Disorders Drugs Global Market Report 2022

https://www.thebusinessresearchcompany.com/report/musculoskeletal-disorder-drugs-global-market-report

About The Business Research Company:

With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.

Contact us at:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 3156230293

Asia +44 2071930708

Europe +44 2071930708

Email us at info@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

Found this article helpful? Share it on:

Updated 2025 Market Reports Released: Trends, Forecasts to 2034 – Early Purchase Your Competitive Edge Today!

What is the Anticipated CAGR of the Gastric Cancer Drugs Market, and What Factors Will Drive It?

The gastric cancer drugs market has grown rapidly in recent years. It is expected to grow from $4.43 billion in 2025 to $5.01 billion in 2025, with a CAGR of 12.9%. This growth can be attributed to higher pharmaceutical R&D expenditure, increasing healthcare spending, strong economic growth in emerging markets, and a rapidly aging population.

The gastric cancer drugs market is expected to grow to $7.6 billion by 2029, at a CAGR of 11.0%. This growth is driven by rising gastric cancer incidence, a strong drug pipeline, increased healthcare spending, and aging populations. Trends include strategic collaborations, AI-driven drug development, next-generation biologics, and the use of CRISPR-Cas9 technology.

What Market Dynamics Are Playing a Key Role in Accelerating the Growth of the gastric cancer drugs Market?

The rise in obesity and smoking-related illnesses is driving the growth of the gastric cancer drugs market. Diet and tobacco consumption are major risk factors for stomach cancer. For example, the UK’s Government Digital Service projected that 25.9% of adults in England were obese in 2022. The growing incidence of gastric cancer is fueling the demand for related treatments.

Explore Comprehensive Insights Into The Global Gastric Cancer Drugs Market With A Free Sample Report:

https://www.thebusinessresearchcompany.com/sample.aspx?id=2603&type=smp

Who Are the Top Companies Contributing to the Growth of the Gastric Cancer Drugs Market?

Major companies operating in the gastric cancer drugs market include:

• F. Hoffmann-La Roche_x000D_

• Eli Lilly and Company_x000D_

• Otsuka Pharmaceutical_x000D_

• Jiangsu HengRui Medicine_x000D_

• Biocon_x000D_

How Are Technological Trends Affecting the Growth and Development of the Gastric Cancer Drugs Market?

In the gastric cancer drugs market, companies are developing advanced therapies. For instance, in November 2023, Merck & Co., Inc., a US-based pharmaceutical company, received FDA approval for KEYTRUDA (pembrolizumab), an anti-PD-1 therapy for treating gastric cancer, specifically HER2-positive cases.

Secure Your Global Gastric Cancer Drugs Market Report Now for Fast and Efficient Delivery!

https://www.thebusinessresearchcompany.com/report/gastric-cancer-drugs-global-market-report

Which Segments Play a Crucial Role in the Expansion of the Gastric Cancer Drugs Market?

The gastric cancer drugs market covered in this report is segmented –

1) By Type: Imatinib, Trastuzumab, Other Types

2) By Route of Administration: Oral, Parenteral

3) By End User: Hospitals, Clinics, Cancer Speciality Centers

Subsegments:

1) By Imatinib: Oral Formulations, Injectable Formulations, Combination Therapies

2) By Trastuzumab: Monotherapy, Combination Therapy With Chemotherapy, Biosimilars Of Trastuzumab

3) By Other Types: Chemotherapy Agents, Targeted Therapy Agents, Immunotherapy Agents, Supportive Care Medications

What Are the Key Regions Powering Growth in the Gastric Cancer Drugs Market?

North America was the largest region in the gastric cancer drugs market in 2025. Middle East is expected to be the largest growing region in the global gastric cancer drugs market share during the forecast period. The regions covered in the gastric cancer drugs market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa

How Is the Gastric Cancer Drugs Market Defined Across Different Regions?

Gastric cancer drugs refer to anti-cancer medications that are taken orally as pills or are injected into a vein (via an IV line or central venous catheter). This treatment is effective for cancer that has spread to organs other than those where it originated since these medications penetrate the bloodstream and reach every part of the body.

Browse Through More Similar Reports By The Business Research Company:

Diuretics Global Market Report 2025

https://www.thebusinessresearchcompany.com/report/diuretics-drugs-global-market-report

Genito-Urinary Drugs Global Market Report 2022

https://www.thebusinessresearchcompany.com/report/genito-urinary-drugs-global-market-report

Musculoskeletal Disorders Drugs Global Market Report 2022

https://www.thebusinessresearchcompany.com/report/musculoskeletal-disorder-drugs-global-market-report

About The Business Research Company:

With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.

Contact us at:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 3156230293

Asia +44 2071930708

Europe +44 2071930708

Email us at info@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

Found this article helpful? Share it on: